Leuprorelin Acetate
GnRH agonist for gynecology and oncology applications. Gold standard for endometriosis, uterine fibroids, and hormone-dependent cancer treatment with sustained testosterone/estrogen suppression.
Leuprorelin Acetate is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) and one of the most widely used GnRH agonists in clinical practice. It acts as a potent inhibitor of gonadotropin secretion, initially causing a transient stimulation followed by sustained suppression of LH and FSH, leading to decreased production of sex steroids. It is indicated for prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and breast cancer.
| Parameter | Specification |
| CAS | 74381-53-6 |
| Molecular Formula | C₆₁H₈₈N₁₆O₁₄ |
| Molecular Weight | 1269.47 g/mol |
| Category | GnRH/Reproductive |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Endometriosis, prostate cancer, uterine fibroids, precocious puberty |
| CAS | 74381-53-6 |
|---|---|
| Applications | Breast Cancer, Endometriosis, Precocious Puberty, Prostate Cancer |
Related products
-
Tirzepatide
CAS: 2023788-19-2Applications: Advanced obesity, metabolic syndrome, Type 2 diabetes -
Pramlintide
CAS: 196078-30-5 -
Cagrilintide
CAS: 1415456-99-3Applications: Amylin, Diabetes adjunct therapy, obesity management, weight management -
Abarelix
CAS: 183552-38-7Applications: Advanced Prostate Cancer, Hormone-dependent Tumors, Testosterone Suppression